DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) is scheduled to release its earnings data after the market closes on Wednesday, November 13th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.14) per share for the quarter.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Performance

DMAC stock opened at $4.33 on Thursday. The stock has a market capitalization of $185.11 million, a price-to-earnings ratio of -8.17 and a beta of 1.46. The stock’s fifty day moving average is $4.26 and its two-hundred day moving average is $3.49. DiaMedica Therapeutics has a 1 year low of $2.12 and a 1 year high of $4.95.

Analyst Ratings Changes

DMAC has been the topic of several analyst reports. Oppenheimer restated an “outperform” rating and issued a $6.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, August 16th. HC Wainwright began coverage on DiaMedica Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $7.00 target price for the company.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.